{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:27:00Z","timestamp":1792092420120,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100021077","name":"Vice Chancellor for Research and Technology, Kerman University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004160","name":"Mazandaran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.seizure.2025.03.004","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T03:04:44Z","timestamp":1741316684000},"page":"66-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Long-term outcomes of treatment with levetiracetam and valproate in idiopathic generalized epilepsy"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-2014","authenticated-orcid":false,"given":"Nasim","family":"Tabrizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Cheraghmakani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Samadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0580-000X","authenticated-orcid":false,"given":"Reza","family":"Alizadeh-Navaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.seizure.2025.03.004_bib0001","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1111\/epi.17410","article-title":"Drug resistance in idiopathic generalized epilepsies: evidence and concepts","volume":"63","author":"Gesche","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.03.004_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109364","article-title":"Drug-resistant idiopathic generalized epilepsy: a meta-analysis of prevalence and risk factors","volume":"146","author":"Jiang","year":"2023","journal-title":"Epilepsy Behav"},{"issue":"Suppl 9","key":"10.1016\/j.seizure.2025.03.004_bib0003","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1528-1167.2005.00327.x","article-title":"Evidence-based treatment of idiopathic generalized epilepsies with older antiepileptic drugs","volume":"46","author":"Hitiris","year":"2005","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2025.03.004_bib0004","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/aian.aian_888_21","article-title":"Current concepts in the management of idiopathic generalized epilepsies","volume":"25","author":"Rathore","year":"2022","journal-title":"Ann Indian Acad Neurol"},{"issue":"18","key":"10.1016\/j.seizure.2025.03.004_bib0005","doi-asserted-by":"crossref","first-page":"e2519","DOI":"10.1212\/WNL.0000000000010644","article-title":"Patterns and prognostic markers for treatment response in generalized epilepsies","volume":"95","author":"Gesche","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.seizure.2025.03.004_bib0006","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40263-020-00698-5","article-title":"Pharmacological management of the genetic generalised epilepsies in adolescents and adults","volume":"34","author":"Stephen","year":"2020","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.seizure.2025.03.004_bib0007","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/practneurol-2018-001955","article-title":"Epilepsy advisory group for the association of british neurologists. Valproate and childbearing potential: new regulations","volume":"18","author":"Sisodiya","year":"2018","journal-title":"Pract Neurol"},{"issue":"11","key":"10.1016\/j.seizure.2025.03.004_bib0008","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamaneurol.2023.3400","article-title":"Levetiracetam vs Lamotrigine as first-line antiseizure medication in female patients with idiopathic generalized epilepsy","volume":"80","author":"Cerulli Irelli","year":"2023","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2025.03.004_bib0009","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ane.13389","article-title":"Levetiracetam as first-line monotherapy for Idiopathic Generalized Epilepsy in women","volume":"143","author":"Ballv\u00e9","year":"2021","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.seizure.2025.03.004_bib0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/ane.13567","article-title":"Treatment outcomes in women with idiopathic generalized epilepsy","volume":"145","author":"Kiiski","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2025.03.004_bib0011","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eplepsyres.2015.11.012","article-title":"Pharmacological outcomes in juvenile myoclonic epilepsy: support for sodium valproate","volume":"119","author":"Chowdhury","year":"2016","journal-title":"Epilepsy Res"},{"issue":"10","key":"10.1016\/j.seizure.2025.03.004_bib0012","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/jnnp-2011-300376","article-title":"KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy","volume":"84","author":"Trinka","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10282","key":"10.1016\/j.seizure.2025.03.004_bib0013","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2025.03.004_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2019.106214","article-title":"Levetiracetam in genetic generalized epilepsy: a prospective unblinded active-controlled trial","volume":"157","author":"Tabrizi","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2025.03.004_bib0015","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fneur.2013.00192","article-title":"Clinical pharmacology and pharmacokinetics of levetiracetam","volume":"4","author":"Wright","year":"2013","journal-title":"Front Neurol"},{"issue":"9596","key":"10.1016\/j.seizure.2025.03.004_bib0016","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"STROBE initiative. The strengthening the reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.seizure.2025.03.004_bib0017","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40263-018-00602-2","article-title":"Treatment of juvenile myoclonic epilepsy in patients of child-bearing potential","volume":"33","author":"Serafini","year":"2019","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.seizure.2025.03.004_bib0018","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamaneurol.2024.0258","article-title":"Risk of major congenital malformations and exposure to antiseizure medication monotherapy","volume":"81","author":"Battino","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2025.03.004_bib0019","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/epi4.12349","article-title":"Comparative effectiveness of antiepileptic drugs in juvenile myoclonicepilepsy","volume":"4","author":"Silvennoinen","year":"2019","journal-title":"Epilepsia Open"},{"issue":"18","key":"10.1016\/j.seizure.2025.03.004_bib0020","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Levetiracetam N01057 study group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.seizure.2025.03.004_bib0021","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/WNF.0000000000000177","article-title":"Levetiracetam and valproate retention rate in juvenile myoclonic epilepsy","volume":"39","author":"Sala-Padr\u00f3","year":"2016","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.seizure.2025.03.004_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107706","article-title":"Response to levetiracetam or lamotrigine in subjects with juvenile myoclonic Epilepsy previously treated with valproic acid: a single center retrospective study","volume":"115","author":"Milano","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.seizure.2025.03.004_bib0023","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/epi4.12321","article-title":"Clinical features and treatment outcomes of juvenile myoclonic epilepsy patients","volume":"4","author":"Zhang","year":"2019","journal-title":"Epilepsia Open"},{"issue":"3","key":"10.1016\/j.seizure.2025.03.004_bib0024","doi-asserted-by":"crossref","first-page":"fcad182","DOI":"10.1093\/braincomms\/fcad182","article-title":"Variation in prognosis and treatment outcome in juvenile myoclonic epilepsy: a Biology of Juvenile Myoclonic Epilepsy Consortium proposal for a practical definition and stratified medicine classifications","volume":"5","author":"Rubboli","year":"2023","journal-title":"Brain Commun"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913112500069X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913112500069X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:20:00Z","timestamp":1775024400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105913112500069X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":24,"alternative-id":["S105913112500069X"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2025.03.004","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes of treatment with levetiracetam and valproate in idiopathic generalized epilepsy","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2025.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}